Philips at ESOC 2022: showcasing integrated solutions across the
stroke care pathway
May 3, 2022
- Suite of solutions across the stroke care pathway are aimed at
improving diagnostic confidence and time to treatment, helping
reduce the risk of a second stroke
- New results on health economic benefits of the ‘Direct to Angio
Suite’ approach presented at ESOC
Amsterdam, the Netherlands – Royal
Philips (NYSE: PHG, AEX: PHIA), a global leader in health
technology, will showcase its latest advances in its integrated
suite of solutions for the treatment of stroke patients at the 2022
European Stroke Organisation Conference (ESOC 2022, May 4-6, Lyon,
France). With its suite of solutions, Philips is connecting
information, technologies and people across the stroke care
pathway, enabling care teams to work quickly and act decisively - a
key factor in providing the best patient treatment.
“Every second counts for someone suffering a stroke, so
optimizing the workflow across the entire care pathway offers the
best chance of improving outcomes,” said Bert van Meurs, Chief
Business Leader for Image Guided Therapy at Philips. “With our
integrated suites, and by using validated AI and cloud
technologies, we can facilitate collaborative care to optimize the
stroke care pathway from diagnosis to treatment.”
Stroke remains the leading cause of disability
Globally, one in four adults over the age of 25 will suffer a
stroke in their lifetime [1]. Stroke is the leading cause of
disability and the second leading cause of death worldwide [2]. 40%
of stroke victims experience moderate to severe impairments , with
another 25% continuing to suffer minor impairments [3].
The key to improving outcomes for stroke patients is to provide
treatment as quickly as possible. Physicians in an emergency stroke
setting are fighting the clock and are under intense pressure to
make optimal treatment decisions. Despite the imperative for
speed, care teams currently lose valuable time due to gaps in
communication, information and access to stroke expertise.
Solutions across the stroke care
pathwayPhilips’ comprehensive stroke suite includes
solutions for stroke monitoring and communication in ambulances,
tele-stroke patient assessment, diagnostic imaging and analysis,
image-guided therapy, neurological monitoring and assessment, and
more. These solutions are aimed at improving diagnostic confidence,
improving time to treatment, and helping reduce the risk of a
second stroke.
In the case of ischemic stroke, CT angiography (CTA) is used for
vessel analysis and CT perfusion (CTP) for the assessment of
ischemic tissue in terms of that which is salvageable (penumbra)
and unsalvageable (infarct core). Spectral CT 7500
can improve diagnostic capabilities for radiologists.
It offers enhanced gray and white matter differentiation
[4], improved image quality for detection of subtle hemorrhage
[5] and may help in detection of ischemic
stroke through enhanced visualization of vascular anatomy.
Philips Neuro suite is based on the company’s Image Guided
Therapy System – Azurion. It is delivering the latest advancements
in interventional neuroradiology, such as the company’s
industry-leading CT-like SmartCT which provides a 3D visualization
and measurement tool to assist interventional neuroradiologists
with diagnosis and treatment, enabling them to get stroke patients
into treatment quickly.Philips is also integrating cloud-based,
end-to-end artificial intelligence-based [6] stroke triage and
management through StrokeViewer – for which it collaborates with
Nico.lab – aiming to improve patient outcomes by optimizing the
stroke workflow.
WE-TRUST global multicenter stroke study To
help accelerate stroke diagnosis and treatment, Philips is
sponsoring the WE-TRUST trial (Workflow optimization to rEduce Time
to endovascular Reperfusion for Ultra-fast Stroke Treatment). In
this trial, a new angio suite imaging protocol, called the Direct
to Angio Suite approach, is implemented to allow for stroke
diagnosis and treatment to occur in the same place. The study will
compare this approach with the conventional workflow of diagnosing
patients for treatment in the CT or MRI suite and then treating
them in a separate angio suite.
“A direct transfer to angiosuite protocol not only minimizes
workflow times and reduces the long term disability in our
patients, but also substantially reduces the associated costs,”
said Dr. Marc Ribó, WE-TRUST Co-Principal Investigator,
Interventional Neurologist at the Vall d’Hebron University Hospital
and Researcher at the Stroke Research Group at the Vall d’Hebron
Research Institute. “The model which we created based on our single
center randomized clinical study data from the ANGIOCAT study and
the cost related data per mRS shows a fast return of investment on
a dedicated angiosuite treating patients in a Direct-To-AngioSuite
workflow.”
Dr. Marc Ribó will present the results of the health economics
of the Direct to Angio Suite approach during the symposium on
Wednesday, May 4 which begins at 13:15 in Salon Pasteur at ESOC.
You can find more information on his presentation here.
Post-stroke remote telemetryHeart rhythm
irregularities can lead to blood clots and increase the risk of
stroke. It can increase the risk of stroke by more than five times
[7], but it often goes undetected since it can be asymptomatic and
may occur infrequently. Therefore, it is important to record the
details of the irregularities especially in the days and
weeks after therapy.
Philips ePatch offers a small unobtrusive sensor and patch
adhered to the patient’s sternum for up to 14 days of continuous,
high-quality ECG recording for reliable diagnosis [8]. Philips also
provides an end-to-end service to support practices to deploy
ePatch, enabling efficient workflows, enhancing the patient
experience and providing robust data analysis using the company’s
cloud-based AI-enabled Cardiologs software.
New research evaluating mobile cardiac outpatient telemetry
(MCOT) as a first-line diagnostic home monitoring solution with
post-cryptogenic stroke patients determined that a 30-day
continuous monitoring program using Philips BioTel Heart MCOT®
patch [9], followed by an implantable loop recorder (ILR), reduced
the total cost per patient with detected AF by approximately
$198,909 [10] compared to monitoring with ILR only. The model also
demonstrated improving AF detection rates while reducing the risk
of secondary stroke. This research strengthens recommendations for
prolonged ECG monitoring for this patient population.
[1] World Stroke Organization[2] Global Burden of Stroke,
PubMed.[3] U.S. National Stroke Association[4] Neuhaus V, et al.
Improvement of image quality in unenhanced dual-layer CT of the
head using virtual monoenergetic images compared with polyenergetic
single-energy CT. Invest Radiol. 2017;52(8):1. DOI:
10.1097/RLI.0000000000000367.[5] Gulko E, et al. Differentiation of
hemorrhage from contrast enhancement using dual-layer spectral CT
in patients transferred for acute stroke. Clin Imaging.
2021;69:75–78. DOI: 10.1016/j.clinimag.2020.06.046. [6] We embrace
the following formal definition of AI (source: HLEG definition
AI)[7] Virani SS, Alonso A, Aparicio HJ, et al. American Heart
Association Council on Epidemiology and Prevention Statistics
Committee and Stroke Statistics Subcommittee. Heart disease and
stroke statistics-2021 update: a report from the American Heart
Association. Circulation. 2021
https://pubmed.ncbi.nlm.nih.gov/33501848/[8] Patient will need to
replace patch on day 5 of wear, or sooner as required[9] Philips
BioTel Heart MCOT® patch is only for sale in the U.S.[10]
Difference in cost per patient with detected AF monitored with ILR
($228,507) minus cost per patient with detected AF patients using
the MCOT patch ($29,598). Medic G, Kotsopoulos N, Connolly MP,
Lavelle J, Norlock V, Wadhwa M, Mohr BA, Derkac WM. Mobile Cardiac
Outpatient Telemetry Patch vs Implantable Loop Recorder in
Cryptogenic Stroke Patients in the US - Cost-Minimization Model.
Med Devices (Auckl). 2021 Dec 18;14:445-458. doi:
10.2147/MDER.S337142. PMID: 34955658; PMCID: PMC8694406.
For further information, please contact:
Joost MalthaPhilips Global Press OfficeTel: +31 610 558
116Email: joost.maltha@philips.com
Fabienne van der FeerPhilips Image Guided TherapyTel: +31 622
698 001Email: fabienne.van.der.feer@philips.com
About Royal Philips Royal Philips (NYSE: PHG,
AEX: PHIA) is a leading health technology company focused on
improving people's health and well-being, and enabling better
outcomes across the health continuum – from healthy living and
prevention, to diagnosis, treatment and home care. Philips
leverages advanced technology and deep clinical and consumer
insights to deliver integrated solutions. Headquartered in the
Netherlands, the company is a leader in diagnostic imaging,
image-guided therapy, patient monitoring and health informatics, as
well as in consumer health and home care. Philips generated 2021
sales of EUR 17.2 billion and employs approximately 79,000
employees with sales and services in more than 100 countries. News
about Philips can be found at www.philips.com/newscenter.
- Philips Azurion with Neuro suite
- Philips Spectral CT7500 MR scanner
- Philips ePatch high-quality ECG recording
Koninklijke Philips NV (BIT:1PHIA)
Historical Stock Chart
From Apr 2024 to May 2024
Koninklijke Philips NV (BIT:1PHIA)
Historical Stock Chart
From May 2023 to May 2024